Abstract
Thymic neoplasms are rare malignant tumors, and the mainstay of treatment for patients with thymic tumors is surgical resection. Chemotherapy is necessary for patients with extensive tumor invasion or metastasis who are unable to undergo complete radical excision. However, only two-thirds of these patients respond to chemotherapy. For those patients who are resistant to chemotherapy, targeted therapy has been proposed as a beneficial alternative. Many genes implicated in tumorigenesis and metastasis have been demonstrated to be therapeutic targets in thymic malignancies. Currently, a number of case reports and small clinical trials have reported that a few inhibitors, such as sorafenib and sunitinib, are effective for the treatment of thymoma. This review describes the current potential drug targets and their roles in the development of thymic malignancy. Drugs that are used for the targeted therapy of thymoma and the results of related clinical trials are addressed. Furthermore, we provide an overview of the screening of specific patients who are suitable for targeted therapy and the efficacy of targeted therapy in patients with refractory or recurrent thymic tumors.
Keywords: Cancer therapy, carcinogenesis, targeted therapy, thymic neoplasms, thymic carcinoma, thymoma.
Current Cancer Drug Targets
Title:Current Drug Targets for Thymic Neoplasms
Volume: 15 Issue: 7
Author(s): Xiao-Ling Xu and Wei-Min Mao
Affiliation:
Keywords: Cancer therapy, carcinogenesis, targeted therapy, thymic neoplasms, thymic carcinoma, thymoma.
Abstract: Thymic neoplasms are rare malignant tumors, and the mainstay of treatment for patients with thymic tumors is surgical resection. Chemotherapy is necessary for patients with extensive tumor invasion or metastasis who are unable to undergo complete radical excision. However, only two-thirds of these patients respond to chemotherapy. For those patients who are resistant to chemotherapy, targeted therapy has been proposed as a beneficial alternative. Many genes implicated in tumorigenesis and metastasis have been demonstrated to be therapeutic targets in thymic malignancies. Currently, a number of case reports and small clinical trials have reported that a few inhibitors, such as sorafenib and sunitinib, are effective for the treatment of thymoma. This review describes the current potential drug targets and their roles in the development of thymic malignancy. Drugs that are used for the targeted therapy of thymoma and the results of related clinical trials are addressed. Furthermore, we provide an overview of the screening of specific patients who are suitable for targeted therapy and the efficacy of targeted therapy in patients with refractory or recurrent thymic tumors.
Export Options
About this article
Cite this article as:
Xu Xiao-Ling and Mao Wei-Min, Current Drug Targets for Thymic Neoplasms, Current Cancer Drug Targets 2015; 15 (7) . https://dx.doi.org/10.2174/1568009615666150616124155
DOI https://dx.doi.org/10.2174/1568009615666150616124155 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Novel Therapeutic Approaches to Target Drug Resistant Tumors
With the development of disciplines such as chemical biology and molecular biology, the genes or proteins closely related to tumor occurrence and development have gradually become clear. Targeted therapies targeting these genes or proteins provide more effective methods for tumor treatment. Tumor targeted drugs generally only act on specific targets ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Rab GTPases, Membrane Trafficking and Diseases
Current Drug Targets TNFα Modulation of Visceral and Spinal Sensory Processing
Current Pharmaceutical Design Sanguinarine: A Double-Edged Sword of Anticancer and Carcinogenesis and Its Future Application Prospect
Anti-Cancer Agents in Medicinal Chemistry A Wnt-ow of Opportunity: Targeting the Wnt/β-Catenin Pathway in Breast Cancer
Current Drug Targets Assessment of Nutritional Status in Cancer – The Relationship Between Body Composition and Pharmacokinetics
Anti-Cancer Agents in Medicinal Chemistry Nanotherapeutics in Neuropathologies: Obstacles, Challenges and Recent Advancements in CNS Targeted Drug Delivery Systems
Current Neuropharmacology New Perspectives in Glioma Immunotherapy
Current Pharmaceutical Design Pharmacogenetics of Non-small Cell Lung Cancer (NSCLC): Time to "Work it Out"?
Current Pharmaceutical Design CRISPR-Cas9, A Promising Therapeutic Tool for Cancer Therapy: A Review
Protein & Peptide Letters Mechanisms Involved in the Protective Effects of Metformin Against Nonalcoholic Fatty Liver Disease
Current Medicinal Chemistry Radiotherapy for Non-Melanoma Skin Cancer
Current Cancer Therapy Reviews Understanding Abnormal c-JNK/p38MAPK Signaling in Amyotrophic Lateral Sclerosis: Potential Drug Targets and Influences on Neurological Disorders
CNS & Neurological Disorders - Drug Targets Bladder Cancer Stem Cells
Current Stem Cell Research & Therapy Gain of Function Effects of Z Alpha-1 Antitrypsin
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Repurposing of Metformin for Cancer Therapy: Updated Patent and Literature Review
Recent Patents on Anti-Cancer Drug Discovery Novel Molecular Targets and Mechanisms Involved in the Invasion and Metastasis of Pancreatic Cancer
Clinical Cancer Drugs Omega-3 Polyunsaturated Fatty Acids and Cancer
Anti-Cancer Agents in Medicinal Chemistry Modulation of Sensitivity to Antitumor Agents by Targeting the MAPK Survival Pathway
Current Pharmaceutical Design A Review of Diabetes Mellitus and Exposure to the Environmental Toxicant Cadmium with an Emphasis on Likely Mechanisms of Action
Current Diabetes Reviews Integrins Modulate Cellular Fibrogenesis at Multiple Levels: Regulation of TGF-β Signaling
Endocrine, Metabolic & Immune Disorders - Drug Targets